DOI: 10.36347/sasjm.2022.v08i10.016

Pages: 754-756

Olanzapine is an atypical antipsychotic with proven efficacy in the treatment of schizophrenia and bipolar disorder. This molecule is known for its metabolic side effects, but it is considered the safest with regard to haematological toxicity. The case of our 28 year old patient, who has been followed anarchically for 5 years for schizophrenia and who presented a thrombocytopenia of 99,000/mm3 within a week of being put on olanzapine without any other associated signs, is one of nine cases published in the literature illustrating this association which is rare but encourages clinicians to institute close haematological monitoring to prevent any life threatening effects.